Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

Delcath Systems, Inc. ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced an update to the ...

Duran Duran say former guitarist Andy Taylor is "fighting as hard as he can" in his ongoing cancer battle. He was diagnosed in 2018.

Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

Prostate cancer cells usually require male androgen hormones, such as testosterone, to grow. Androgen deprivation therapy ...

New research maps the global burden of male cancers from 1990 to 2040, showing how aging, lifestyle, and healthcare access ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...